Patent ID: 6224891
Filing Date: 2001-05-01
Classification: A61K,A61P,Y02A

Abstract:
A method to prevent or ameliorate one or more conditions mediated by enterohemorrhagic E. coli in a patient suffering from or susceptible to said condition, comprising the steps of:a) administering to the patient an amount of at least one shiga-like toxin (SLT) binding oligosaccharide sequence covalently attached to a pharmaceutically acceptable inert support (oligosaccharide-support), wherein said oligosaccharide sequence blinds SLT and said amount is effective to provide neutralization and elimination of the SLT present in the gut of the patient wherein said oligosaccharide-support is an 8-methoxycarbonyloctyl oligosaccharide covalently coupled to derivatized silica particles; and, after step a)b) simultaneously administering to the patient an amount of at least one antibiotic, said amount of said antibiotic being effective to kill the pathogenic E. coli in the patient and an amount of at least one SLT binding oligosaccharide sequence covalently attached to a pharmaceutically acceptable inert support (oligosaccharide-support), wherein said oligosaccharide sequence binds SLT and said amount is effective to provide neutralization and elimination of the SLT present in the gut of the patient wherein said oligosaccharide-support is an 8-methoxycarbonyloctyl oligosaccharide covalently coupled to derivatized silica particles, andwherein, following each administration, the SLT bound to said oligosaccharide-support is capable of being eliminated from the gastrointestinal tract.